Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2022-03-08 00:00:00 ET · period of report 2022-03-04 · accession 0001209191-22-017316 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-03-08 | 2022-03-04+ | XENE | EMPFIELD JAMES R. | EVP, Drug Discovery | M - OptEx | $7.43 | +67.5K | 51.8K | New | +$501.4K |
| DM | 2022-03-08 | 2022-03-04+ | XENE | EMPFIELD JAMES R. | EVP, Drug Discovery | F - Tax | $30.72 | -16.3K | 42.9K | -28% | -$501.7K |
| DM | 2022-03-08 | 2022-03-04+ | XENE | EMPFIELD JAMES R. | EVP, Drug Discovery | S - Sale+OE | $30.63 | -51.2K | 10.0K | -84% | -$1.57M |
| DM | 2022-03-08 | 2022-03-04+ | XENE | EMPFIELD JAMES R. | EVP, Drug Discovery | M - OptEx | $0.00 | -67.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-03-04 | M | A | 25,000 | $8.40 | 35,000 | D | — | — | |
| 2 | Common | Common Shares | 2022-03-04 | F | D | 6,685 | $31.42 | 28,315 | D | — | — | (F1) Represents the closing price of the Company's common shares on March 3, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. |
| 3 | Common | Common Shares | 2022-03-04 | S | D | 18,315 | $30.79 | 10,000 | D | — | — | (F2) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.21 to $31.0296, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 4 | Common | Common Shares | 2022-03-07 | M | A | 2,500 | $8.40 | 12,500 | D | — | — | |
| 5 | Common | Common Shares | 2022-03-07 | F | D | 695 | $30.23 | 11,805 | D | — | — | (F3) Represents the closing price of the Company's common shares on March 4, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. |
| 6 | Common | Common Shares | 2022-03-07 | M | A | 40,000 | $6.76 | 51,805 | D | — | — | |
| 7 | Common | Common Shares | 2022-03-07 | F | D | 8,952 | $30.23 | 42,853 | D | — | — | (F3) Represents the closing price of the Company's common shares on March 4, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. |
| 8 | Common | Common Shares | 2022-03-07 | S | D | 1,805 | $30.62 | 41,048 | D | — | — | |
| 9 | Common | Common Shares | 2022-03-07 | S | D | 31,048 | $30.54 | 10,000 | D | — | — | (F4) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.5161 to $30.6208, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 10 | Derivative | Stock Option (Right to Buy) | 2022-03-04 | M | D | 25,000 | $0.00 | 0 | D | $8.40 · — to 2027-03-12 | 25,000 Common Shares | (F5) Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. |
| 11 | Derivative | Stock Option (Right to Buy) | 2022-03-07 | M | D | 40,000 | $0.00 | 0 | D | $6.76 · — to 2026-02-07 | 40,000 Common Shares | (F6) Vesting 25% on February 9, 2017 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. |
| 12 | Derivative | Stock Option (Right to Buy) | 2022-03-07 | M | D | 2,500 | $0.00 | 0 | D | $8.40 · — to 2027-03-12 | 2,500 Common Shares | (F5) Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. |